Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05800964 · ClinicalTrials.gov registry record · Phase 1
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT05800964 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 37 participants.
The verdict
NCT05800964, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The primary objective of this study is to: * Evaluate the safety and tolerability of AMG 305 in adult participants * Determine the optimal biologically active dose (OBD), at or below the maximum tolerated dose (MTD) with MTD 1 as the maximum tolerated starting dose and MTD 2 as the maximum tolerated target dose * Determine the recommended phase 2 dose (RP2D)
Interventions
- DRUG AMG 305
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2023-06-13 |
| Est. Completion | 2026-01-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05800964
The ClinicalTrials.gov registry entry for NCT05800964 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 305 is the first listed.
NCT05800964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05800964 about?
NCT05800964 is a clinical study titled "Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors". The primary objective of this study is to: * Evaluate the safety and tolerability of AMG 305 in adult participants * Determine the optimal biologically active dose (OBD), at or below the maximum tolerated dose (MTD) with MTD 1 as the maximum tolerated starting dose and MTD 2 as the maximum tolerate...
What is the current status of trial NCT05800964?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2023-06-13. Estimated completion is 2026-01-22.
What interventions are being tested in trial NCT05800964?
The interventions under investigation include: AMG 305 (DRUG).
Who is sponsoring clinical trial NCT05800964?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.